The company is seeking approval from the US regulator for Vraylar (cariprazine) as an add-on to conventional antidepressant therapy in people with MDD who may be struggling to control symptoms ...

Allergan and Richter push ahead despite PhIII fail for depression drug Vraylar brought in $1.73 billion for AbbVie in 2021 and is indicated for bipolar I disorder and schizophrenia. The therapy ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

and the pharma says it will lean on its marketing work for its atypical antipsychotic drug Vraylar to position this therapy while also looking to carve out a new message. “We have put a lot of ...

Several MDD patients experience partial response to their antidepressant therapy as they still have depressive symptoms. The approval of Vraylar for MDD offers a new adjunctive treatment option ...

Notably, Vraylar is already approved in the United States and the EU for acute therapy of manic or mixed episodes associated with bipolar I disorder as well as for schizophrenia. If approved for ...

Hence, Vraylar’s label expansion as a maintenance therapy will cater to the hugely unmet need of patients, requiring a long-term treatment option for the disease. Allergan carries a Zacks Rank ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Vraylar (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in ...